Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK plus NSCLC in South Korea J. E. Lee, J. H. Nam,S. H. Kwon,B-K. Kim,S-M. HaANNALS OF ONCOLOGY（2023）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
